Led · Series A · Jun 2026

Rapalogix Health develops a TORC1-targeting platform aimed at restoring youthful cellular function in skin and is building both a prescription therapeutics pipeline and professional skincare products. Its lead molecule, RLX-201, is a patented pro-longevity compound and powers the Re-Q Pro-Longevity Face Serum, which launched nationally on May 14, 2026 and is available at dermatology and aesthetic practices across the United States. The company is advancing RLX-202 as its next prescription therapeutic and is using Series A proceeds to fund IND-enabling studies for that candidate. Rapalogix plans to use capital from the financing to expand Re-Q Health nationally. The company has received multiple industry recognitions in 2026, including awards at IMCAS, Octane’s Aesthetics Tech Forum, INNOCOS, and AMWC. The business is led by Co-Founder and CEO Rahul Mehta, PhD.

Participated · Series A · Jun 2026

Cuprum Metals develops a patented, water-based chemical leaching technology that operates at room temperature and pressure and can be tuned as a chemical "tool kit" for a variety of ores and tailings. The process is reported to achieve recoveries typically exceeding 75% from predominantly chalcopyrite ore within 100 days and is effective on oxide ores while consuming less acid than standard oxide leach processes. Cuprum's approach can operate using seawater and does not require heating or biological processes, enabling recovery from primary sulfide ores, secondary sulfide tailings, smelter slags and previously processed materials. Test work has been conducted on mines in South Africa, the US, Chile and Australia with strong results. The company was founded in 2024 and is Delaware-based with a Winter Park, Fla. press office; it plans to use Series A proceeds to scale commercial deployment, expand technical capabilities, hire key personnel and grow its customer base. The firm positions its technology as a flexible solution to improve recovery pathways and reduce operating and capital costs for copper assets.

Participated · Series C · Feb 2026

Founded in 2016, Skyryse is an El Segundo, California–based aviation automation company focused on SkyOS, a flight control operating system that replaces dozens of traditional gauges and switches with touchscreen-based automation. The system handles take-off, landing, hover, and engine-out emergencies, while still keeping a pilot in the loop, thereby enhancing safety and reducing pilot workload. Skyryse has already integrated SkyOS into platforms ranging from civilian helicopters to U.S. military Black Hawk helicopters and has inked integration contracts with United Rotorcraft, Air Methods, and Mitsubishi Corporation. The company is nearing the final stages of FAA certification after receiving final design approval for its flight control computers. New funding will accelerate SkyOS deployment across additional aircraft types and support the remaining certification testing. Including the latest round, Skyryse has secured more than $605 million in equity financing and now carries a $1.15 billion valuation.

Participated · Series B · Jan 2026

Mirador Therapeutics is focused on delivering first- and best-in-class therapeutics for Crohn’s disease, ulcerative colitis, rheumatoid arthritis, idiopathic pulmonary fibrosis, and other immuno-fibrotic conditions. Its Mirador360 (M360) discovery and development engine combines more than 2.5 million patient profiles with advanced machine learning to uncover novel targets, stratify patients, and design rational drug combinations. In less than two years, the company has advanced multiple clinical-stage assets and is pursuing a parallel development strategy that aims to generate ten or more clinical readouts by the end of 2027. Management positions the approach as a step-change over incremental monotherapies, seeking to redefine precision medicine in immunology and inflammation. Mirador has raised over $650 million since launching in March 2024, enabling it to fund proof-of-concept studies across its current portfolio and add new pipeline candidates. The company operates with an emphasis on capital efficiency and disciplined execution to sustain momentum. Mirador is headquartered in San Diego, California.

Participated · Series E · Nov 2025

Ursa Major provides flight-proven propulsion solutions for hypersonics, solid rocket motors, space mobility, and launch applications. Headquartered in Berthoud, Colorado, with additive manufacturing operations in Youngstown, Ohio, the company leverages advanced production techniques and flexible architectures to serve land, air, sea, and space domains. Recent milestones include multiple successful flights of its hypersonic engines and tactical missiles, completion of tests for space-propulsion systems, and the addition of industry veterans Ronald Sugar and Gilman Louie to its board. Through the first three quarters of 2025, Ursa Major secured more than $115 million in bookings from government and commercial customers such as the U.S. Department of Defense, the U.S. Air Force Research Laboratory, Stratolaunch, and BAE Systems. The fresh capital will be used to scale manufacturing capacity, accelerate production of throttleable, storable liquid-fueled hypersonic and space-based defense solutions, and expand solid-rocket-motor output. The company positions itself as a modern alternative to legacy defense suppliers, aiming to deliver capabilities faster and at lower cost.